- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07671495
Adjuvant Therapy of Skin Melanoma With Alpha Interferon and Naderin (ATSMAIN)
Protocol of Clinical Trial of EAFO 2012: Adjuvant Therapy of Skin Melanoma With Use of Alpha Interferon and Naderin
The goal of this clinical trial is to learn if adding alpha interferon to standard treatment works to prevent skin melanoma from coming back after surgery. The study will also learn if different doses of alpha interferon work better than others.
The main questions it aims to answer are:
- Does alpha interferon help people with melanoma live longer without the cancer returning?
- Does a higher dose of alpha interferon work better than a lower dose?
- How does alpha interferon affect the immune system? Researchers will compare six different treatment approaches to see which one works best.
Participants will:
- Have surgery to remove their melanoma
- Receive one of six different treatments after surgery:
- Radiation therapy (40 Gy)
- Low-dose interferon (3 million IU)
- Surgery alone (no additional treatment)
- High-dose interferon (9 million IU/m² IV)
- Low-dose interferon with chemotherapy (dacarbazine + cisplatin)
- Chemotherapy alone (dacarbazine + cisplatin)
- Have regular check-ups to see if the cancer returns
- Have blood tests to check immune system function Key finding: The study will determine which treatment approach provides the best chance of survival without cancer recurrence.
Descripción general del estudio
Estado
Descripción detallada
Study Rationale Cutaneous melanoma has a clinically meaningful risk of recurrence after complete surgical resection, particularly in higher-risk disease. Interferon alfa has historically been investigated as adjuvant immunotherapy in melanoma; randomized trials and meta-analyses have shown modest improvements in relapse-related endpoints with clinically important toxicity, and no consistent evidence that higher-dose strategies provide greater benefit than lower-dose strategies.
This study compared multiple adjuvant approaches used in local practice, including differing interferon dose intensities and combinations with cytotoxic chemotherapy or radiotherapy, to explore their comparative associations with recurrence and survival outcomes.
Study Design and Setting This was a single-country, comparative interventional study conducted after definitive surgery for cutaneous melanoma. Participants were allocated to one of six post-operative management groups based on clinical factors and treatment availability (non-randomized, open-label assignment).
Interventions (post-operative groups)
After surgical resection, participants received one of the following:
Adjuvant radiotherapy to the surgical bed: total dose 40 Gy.
Low-dose interferon alfa: 3 million IU subcutaneously on a scheduled regimen.
Observation / surgery alone (no adjuvant therapy).
Higher-dose interferon alfa: 9 million IU/m² intravenously on a scheduled regimen.
Low-dose interferon alfa + polychemotherapy: dacarbazine + cisplatin.
Polychemotherapy alone: dacarbazine + cisplatin. (Administration schedules, cycle lengths, and duration should be specified in the protocol or an accessible supporting document, consistent with protocol reporting standards.)
Assessments and Follow-up
Participants underwent baseline clinical evaluation after surgery and were followed at prespecified intervals for:
Disease status/recurrence surveillance (clinical assessments and imaging per local standard schedule).
Safety monitoring including treatment-emergent adverse events.
Immune monitoring via peripheral blood sampling with lymphocyte subset evaluation (including CD4/CD8 ratio) at baseline and predefined follow-up timepoints.
Outcomes (high-level; avoid duplicating Outcome Measures section) The study evaluated time-to-event and proportion-based clinical outcomes (recurrence and survival endpoints), safety/tolerability of each adjuvant approach, and longitudinal changes in immune markers.
Statistical Considerations (high-level) Time-to-event outcomes were planned for analysis using Kaplan-Meier methods with between-group comparisons using log-rank testing. Immune marker changes were planned for within- and between-group comparisons using parametric or nonparametric methods depending on distributional assumptions. A two-sided significance threshold of p < 0.05 was prespecified.
Limitations (protocol-relevant, non-results) Because treatment assignment was non-randomized, comparative estimates between groups are vulnerable to confounding by indication and selection bias. Interpretation of between-group differences therefore requires caution and may require adjustment methods (e.g., multivariable models/propensity approaches) if covariates were collected and sample size permits.
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 2
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Descripción
Inclusion Criteria:
• Histologically confirmed diagnosis of skin melanoma (stages I-IV according to TNM classification)
- Underwent complete surgical resection of primary tumor with negative margins
- Age 18 years or older
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- Life expectancy of at least 6 months
- Adequate bone marrow function: absolute neutrophil count ≥ 1.5 × 10⁹/L, platelet count ≥ 100 × 10⁹/L, hemoglobin ≥ 90 g/L
- Adequate hepatic function: bilirubin ≤ 1.5 × upper limit of normal (ULN), transaminases ≤ 2.5 × ULN
- Adequate renal function: creatinine ≤ 1.5 × ULN or creatinine clearance ≥ 50 mL/min
- Willing and able to provide written informed consent
- Willing to comply with study procedures and follow-up schedule
Exclusion Criteria:
• Presence of distant metastases at the time of diagnosis (except for stage IV patients included per protocol)
- Prior immunotherapy, chemotherapy, or radiotherapy for melanoma
- History of other malignant neoplasms within the past 5 years (except non-melanoma skin cancer or carcinoma in situ of the cervix)
- Severe or uncontrolled organ dysfunction (cardiac, hepatic, renal, pulmonary)
- Active infection requiring systemic therapy
- Known hypersensitivity to interferon-alpha or any study medications
- Known hypersensitivity to dacarbazine, cisplatin, or any excipients
- Pregnancy or breastfeeding
- Psychiatric or cognitive impairment that would interfere with study participation
- Participation in another interventional clinical trial within 30 days prior to enrollment
- Any condition that, in the investigator's opinion, would compromise participant safety or interfere with study objectives
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Único
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Surgery + Radiotherapy
Surgical resection of primary melanoma with wide excision (4-5 cm margin on trunk, 3 cm on head/neck) followed by adjuvant radiotherapy.
Radiation: external beam gamma therapy, 2 Gy daily fraction, total dose 40 Gy to primary site, 20 Gy to regional lymph node area.
Indicated for localized melanoma (T1-2N0M0) with Clark invasion level I-II.
n=49 patients.
|
Wide excision of primary skin melanoma under general intravenous anesthesia.
Incision margin: 4-5 cm from visible tumor edge on trunk, 3 cm on head and neck, excised as a single block with subcutaneous fat and superficial fascia.
For lower extremity melanoma in 7 patients, wide excision performed without skin closure (open wound management).
Regional lymphadenectomy (Duke's operation for inguinal area or axillary lymphadenectomy) performed if enlarged regional lymph nodes present or for Clark invasion level III-IV
Otros nombres:
External beam gamma radiotherapy delivered to primary melanoma site and regional lymph node area.
Regimen: 2 Gray (Gy) per fraction daily.
Total dose: 40 Gy to primary tumor site, 20 Gy to regional lymph node area.
Indicated only for localized melanoma with Clark invasion level I-II (T1-2N0M0).
Not recommended for deeper invasion (T3-4N0M0) as it may accelerate disease progression
Otros nombres:
Monitoring of cellular immunity parameters including CD3, CD4, CD8, and CD4/CD8 ratio (immune regulatory index) using monoclonal antibodies.
Performed at baseline pre-surgery, then at 1 month post-surgery, every 2 months for first year, and every 3 months for subsequent 5 years.
CD4/CD8 ratio <1.3 indicates immunosuppression requiring intervention.
Ratio decline over 3-6 months predicts disease recurrence in 98.2% of cases.
Otros nombres:
Non-invasive dermatoscopy device (Menard, Japan) for detecting subclinical intradermal satellite metastases in melanoma patients.
Provides 40-80x magnification with surface and deep imaging modes.
Enables photo/video capture and analysis.
Sensitivity: 75.0±4.1% for detecting intradermal metastases vs. 26.0±3.4% with visual examination alone.
Helps determine appropriate surgical margins.
Priority certificate No.2009/1105.1 dated 04.09.2009.
Otros nombres:
|
|
Experimental: Surgery + Low-Dose IFN-α
Surgical resection followed by low-dose interferon alfa immunotherapy.
Regimen: 3 million IU intradermal daily until cumulative dose 30 million IU, then maintenance therapy (3 million IU single dose) administered only when CD4/CD8 ratio drops below 1.3.
Indicated for localized melanoma (T1-4N0M0) with low/intermediate metastasis risk.
n=38 patients
|
Wide excision of primary skin melanoma under general intravenous anesthesia.
Incision margin: 4-5 cm from visible tumor edge on trunk, 3 cm on head and neck, excised as a single block with subcutaneous fat and superficial fascia.
For lower extremity melanoma in 7 patients, wide excision performed without skin closure (open wound management).
Regional lymphadenectomy (Duke's operation for inguinal area or axillary lymphadenectomy) performed if enlarged regional lymph nodes present or for Clark invasion level III-IV
Otros nombres:
Monitoring of cellular immunity parameters including CD3, CD4, CD8, and CD4/CD8 ratio (immune regulatory index) using monoclonal antibodies.
Performed at baseline pre-surgery, then at 1 month post-surgery, every 2 months for first year, and every 3 months for subsequent 5 years.
CD4/CD8 ratio <1.3 indicates immunosuppression requiring intervention.
Ratio decline over 3-6 months predicts disease recurrence in 98.2% of cases.
Otros nombres:
Non-invasive dermatoscopy device (Menard, Japan) for detecting subclinical intradermal satellite metastases in melanoma patients.
Provides 40-80x magnification with surface and deep imaging modes.
Enables photo/video capture and analysis.
Sensitivity: 75.0±4.1% for detecting intradermal metastases vs. 26.0±3.4% with visual examination alone.
Helps determine appropriate surgical margins.
Priority certificate No.2009/1105.1 dated 04.09.2009.
Otros nombres:
Recombinant interferon alfa (IFN-α) immunotherapy administered in two dosing regimens.
Low-dose regimen: 3 million IU intradermal daily until cumulative 30 million IU, then maintenance 3 million IU single dose only when CD4/CD8 ratio <1.3.
High-dose regimen: 9 million IU/m² intravenous every 2 days for 4 total doses.
High-dose regimen associated with severe adverse events (fever 39-40°C, headache, nausea, cardiotoxicity, hepatotoxicity, nephrotoxicity, leukopenia) leading to treatment discontinuation in 29.6% of patients.
Otros nombres:
|
|
Comparador activo: Surgery Alone (Control)
Surgical resection only, no adjuvant therapy.
Wide excision of primary melanoma with margins 4-5 cm on trunk, 3 cm on head/neck.
Regional lymphadenectomy performed if enlarged nodes present.
Indicated for localized melanoma (T1-4N0M0) with low/intermediate metastasis risk as control group.
n=64 patients.
|
Wide excision of primary skin melanoma under general intravenous anesthesia.
Incision margin: 4-5 cm from visible tumor edge on trunk, 3 cm on head and neck, excised as a single block with subcutaneous fat and superficial fascia.
For lower extremity melanoma in 7 patients, wide excision performed without skin closure (open wound management).
Regional lymphadenectomy (Duke's operation for inguinal area or axillary lymphadenectomy) performed if enlarged regional lymph nodes present or for Clark invasion level III-IV
Otros nombres:
Monitoring of cellular immunity parameters including CD3, CD4, CD8, and CD4/CD8 ratio (immune regulatory index) using monoclonal antibodies.
Performed at baseline pre-surgery, then at 1 month post-surgery, every 2 months for first year, and every 3 months for subsequent 5 years.
CD4/CD8 ratio <1.3 indicates immunosuppression requiring intervention.
Ratio decline over 3-6 months predicts disease recurrence in 98.2% of cases.
Otros nombres:
Non-invasive dermatoscopy device (Menard, Japan) for detecting subclinical intradermal satellite metastases in melanoma patients.
Provides 40-80x magnification with surface and deep imaging modes.
Enables photo/video capture and analysis.
Sensitivity: 75.0±4.1% for detecting intradermal metastases vs. 26.0±3.4% with visual examination alone.
Helps determine appropriate surgical margins.
Priority certificate No.2009/1105.1 dated 04.09.2009.
Otros nombres:
|
|
Experimental: Surgery + High-Dose IFN-α
Surgical resection followed by high-dose interferon alfa immunotherapy.
Regimen: 9 million IU/m² intravenous every 2 days for a total of 4 doses.
Indicated for locoregional melanoma (T3-4N0-1M0) with intermediate/high metastasis risk.
Treatment discontinued in 29.6% of patients due to severe adverse events (hepatotoxicity, nephrotoxicity, cardiotoxicity, flu-like syndrome, leukopenia).
n=37 patients.
|
Wide excision of primary skin melanoma under general intravenous anesthesia.
Incision margin: 4-5 cm from visible tumor edge on trunk, 3 cm on head and neck, excised as a single block with subcutaneous fat and superficial fascia.
For lower extremity melanoma in 7 patients, wide excision performed without skin closure (open wound management).
Regional lymphadenectomy (Duke's operation for inguinal area or axillary lymphadenectomy) performed if enlarged regional lymph nodes present or for Clark invasion level III-IV
Otros nombres:
Monitoring of cellular immunity parameters including CD3, CD4, CD8, and CD4/CD8 ratio (immune regulatory index) using monoclonal antibodies.
Performed at baseline pre-surgery, then at 1 month post-surgery, every 2 months for first year, and every 3 months for subsequent 5 years.
CD4/CD8 ratio <1.3 indicates immunosuppression requiring intervention.
Ratio decline over 3-6 months predicts disease recurrence in 98.2% of cases.
Otros nombres:
Non-invasive dermatoscopy device (Menard, Japan) for detecting subclinical intradermal satellite metastases in melanoma patients.
Provides 40-80x magnification with surface and deep imaging modes.
Enables photo/video capture and analysis.
Sensitivity: 75.0±4.1% for detecting intradermal metastases vs. 26.0±3.4% with visual examination alone.
Helps determine appropriate surgical margins.
Priority certificate No.2009/1105.1 dated 04.09.2009.
Otros nombres:
Recombinant interferon alfa (IFN-α) immunotherapy administered in two dosing regimens.
Low-dose regimen: 3 million IU intradermal daily until cumulative 30 million IU, then maintenance 3 million IU single dose only when CD4/CD8 ratio <1.3.
High-dose regimen: 9 million IU/m² intravenous every 2 days for 4 total doses.
High-dose regimen associated with severe adverse events (fever 39-40°C, headache, nausea, cardiotoxicity, hepatotoxicity, nephrotoxicity, leukopenia) leading to treatment discontinuation in 29.6% of patients.
Otros nombres:
|
|
Experimental: Surgery + Low-Dose IFN-α + Polychemotherapy
Surgical resection followed by sequential immunochemotherapy.
Phase 1: Low-dose interferon alfa 3 million IU intradermal daily to cumulative 30 million IU.
Phase 2: 6 cycles of polychemotherapy (every 21 days): dacarbazine 1400 mg IV + cisplatin 50 mg IV.
Indicated for locoregional melanoma (T3-4N0-1M0) with intermediate/high metastasis risk.
n=47 patients.
|
Wide excision of primary skin melanoma under general intravenous anesthesia.
Incision margin: 4-5 cm from visible tumor edge on trunk, 3 cm on head and neck, excised as a single block with subcutaneous fat and superficial fascia.
For lower extremity melanoma in 7 patients, wide excision performed without skin closure (open wound management).
Regional lymphadenectomy (Duke's operation for inguinal area or axillary lymphadenectomy) performed if enlarged regional lymph nodes present or for Clark invasion level III-IV
Otros nombres:
Monitoring of cellular immunity parameters including CD3, CD4, CD8, and CD4/CD8 ratio (immune regulatory index) using monoclonal antibodies.
Performed at baseline pre-surgery, then at 1 month post-surgery, every 2 months for first year, and every 3 months for subsequent 5 years.
CD4/CD8 ratio <1.3 indicates immunosuppression requiring intervention.
Ratio decline over 3-6 months predicts disease recurrence in 98.2% of cases.
Otros nombres:
Non-invasive dermatoscopy device (Menard, Japan) for detecting subclinical intradermal satellite metastases in melanoma patients.
Provides 40-80x magnification with surface and deep imaging modes.
Enables photo/video capture and analysis.
Sensitivity: 75.0±4.1% for detecting intradermal metastases vs. 26.0±3.4% with visual examination alone.
Helps determine appropriate surgical margins.
Priority certificate No.2009/1105.1 dated 04.09.2009.
Otros nombres:
Recombinant interferon alfa (IFN-α) immunotherapy administered in two dosing regimens.
Low-dose regimen: 3 million IU intradermal daily until cumulative 30 million IU, then maintenance 3 million IU single dose only when CD4/CD8 ratio <1.3.
High-dose regimen: 9 million IU/m² intravenous every 2 days for 4 total doses.
High-dose regimen associated with severe adverse events (fever 39-40°C, headache, nausea, cardiotoxicity, hepatotoxicity, nephrotoxicity, leukopenia) leading to treatment discontinuation in 29.6% of patients.
Otros nombres:
Alkylating agent chemotherapy.
Administered intravenously at 1400 mg per cycle.
Used in combination with cisplatin for adjuvant polychemotherapy.
Cycle repeats every 21 days for total of 6 cycles.
Common adverse effects: nausea, vomiting, stomatitis, alopecia, short-term diarrhea.
Otros nombres:
Platinum-based chemotherapy agent.
Administered intravenously at 50 mg per cycle.
Used in combination with dacarbazine for adjuvant polychemotherapy.
Cycle repeats every 21 days for total of 6 cycles.
Adverse effects: nausea, vomiting, nephrotoxicity (managed with hydration), ototoxicity
Otros nombres:
|
|
Comparador activo: Surgery + Polychemotherapy Alone (Control)
Surgical resection followed by adjuvant polychemotherapy alone (control group for locoregional melanoma).
Regimen: 6 cycles every 21 days of dacarbazine 1400 mg IV + cisplatin 50 mg IV.
Indicated for locoregional melanoma (T3-4N0-1M0) with intermediate/high metastasis risk.
n=43 patients.
|
Wide excision of primary skin melanoma under general intravenous anesthesia.
Incision margin: 4-5 cm from visible tumor edge on trunk, 3 cm on head and neck, excised as a single block with subcutaneous fat and superficial fascia.
For lower extremity melanoma in 7 patients, wide excision performed without skin closure (open wound management).
Regional lymphadenectomy (Duke's operation for inguinal area or axillary lymphadenectomy) performed if enlarged regional lymph nodes present or for Clark invasion level III-IV
Otros nombres:
Monitoring of cellular immunity parameters including CD3, CD4, CD8, and CD4/CD8 ratio (immune regulatory index) using monoclonal antibodies.
Performed at baseline pre-surgery, then at 1 month post-surgery, every 2 months for first year, and every 3 months for subsequent 5 years.
CD4/CD8 ratio <1.3 indicates immunosuppression requiring intervention.
Ratio decline over 3-6 months predicts disease recurrence in 98.2% of cases.
Otros nombres:
Non-invasive dermatoscopy device (Menard, Japan) for detecting subclinical intradermal satellite metastases in melanoma patients.
Provides 40-80x magnification with surface and deep imaging modes.
Enables photo/video capture and analysis.
Sensitivity: 75.0±4.1% for detecting intradermal metastases vs. 26.0±3.4% with visual examination alone.
Helps determine appropriate surgical margins.
Priority certificate No.2009/1105.1 dated 04.09.2009.
Otros nombres:
Alkylating agent chemotherapy.
Administered intravenously at 1400 mg per cycle.
Used in combination with cisplatin for adjuvant polychemotherapy.
Cycle repeats every 21 days for total of 6 cycles.
Common adverse effects: nausea, vomiting, stomatitis, alopecia, short-term diarrhea.
Otros nombres:
Platinum-based chemotherapy agent.
Administered intravenously at 50 mg per cycle.
Used in combination with dacarbazine for adjuvant polychemotherapy.
Cycle repeats every 21 days for total of 6 cycles.
Adverse effects: nausea, vomiting, nephrotoxicity (managed with hydration), ototoxicity
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Recurrence-free survival
Periodo de tiempo: Up to 5 years following surgical resection
|
Time from surgical resection to first documented recurrence of melanoma (local, regional, or distant) or death from any cause, whichever occurs first.
Assessed through clinical examination, imaging studies, and histopathological confirmation when applicable.
|
Up to 5 years following surgical resection
|
|
5-year overall survival
Periodo de tiempo: 5 years following surgical resection
|
Proportion of participants alive at 5 years following surgical resection.
Survival status assessed through clinical follow-up visits and medical records review.
|
5 years following surgical resection
|
|
Change in CD4/CD8 Ratio
Periodo de tiempo: Baseline and at 6 months post-treatment
|
Change in the ratio of CD4-positive to CD8-positive T lymphocytes from baseline to post-treatment.
Measured by flow cytometry using peripheral blood samples.
Assesses immunologic response to interferon-alpha therapy.
|
Baseline and at 6 months post-treatment
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Incidence of treatment-related adverse events
Periodo de tiempo: Through treatment completion, up to 12 months
|
Proportion of participants experiencing treatment-related adverse events, including severity grading according to Common Terminology Criteria for Adverse Events (CTCAE).
Particular focus on toxicity leading to treatment discontinuation.
|
Through treatment completion, up to 12 months
|
|
Time to recurrence
Periodo de tiempo: Up to 5 years following surgical resection
|
Time from surgical resection to first documented recurrence of melanoma, measured in months.
Participants without recurrence are censored at the date of last follow-up.
|
Up to 5 years following surgical resection
|
|
Disease-free survival
Periodo de tiempo: Up to 5 years following surgical resection
|
Time from surgical resection to first recurrence, second primary melanoma, or death from any cause, whichever occurs first.
|
Up to 5 years following surgical resection
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Neoplasias por sitio
- Neoplasias
- Neoplasias por tipo histológico
- Enfermedades de la piel
- Tumores neuroectodérmicos
- Neoplasias De Células Germinales Y Embrionarias
- Neoplasias De Tejido Nervioso
- Tumores neuroendocrinos
- Nevos y Melanomas
- Neoplasias De La Piel
- Enfermedades de la piel y del tejido conectivo
- Melanoma
- Péptidos
- Aminoácidos, péptidos y proteínas
- Proteínas
- Químicos orgánicos
- Compuestos heterocíclicos, 1 anillo
- Compuestos heterocíclicos
- Técnicas de investigación
- Terapéutica
- Técnicas de laboratorio clínico
- Técnicas y procedimientos de diagnóstico
- Diagnóstico
- Azoles
- Recuento de células
- Técnicas citológicas
- Pruebas hematológicas
- Fenómenos fisiológicos celulares
- Fenómenos fisiológicos de sangre
- Fenómenos fisiológicos circulatorios y respiratorios
- Recuento de leucocitos
- Factores biológicos
- Triazenes
- Imidazoles
- Químicos inorgánicos
- Compuestos de cloro
- Compuestos de nitrógeno
- Técnicas de química, analítica
- Péptidos de señalización intercelular y proteínas
- Compuestos de platino
- Radioterapia
- Separación celular
- Técnicas inmunológicas
- Citocinas
- Terapia de modalidad combinada
- Interferón tipo I
- Interferones
- Recuento de glóbulos
- Fotometría
- Pruebas inmunológicas
- Monitoreo, fisiológico
- Fenómenos del sistema inmunitario
- Fluorometría
- Mediciones luminiscentes
- Recuento de linfocitos
- Citofotometría
- CD4 Lymphocyte Count
- Dacarbazina
- Cisplatino
- Interferón alfa
- Radioterapia, adyuvante
- Citometría de flujo
- Monitorización, Inmunológica
- CD4-CD8 Ratio
Otros números de identificación del estudio
- 5
- EAFO Protocol 2012 (Otro identificador: EAFO)
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .